Longitudinal performance in cervical cancer screening of an HPV mRNA assay for detection of severe lesions occurring up to seven years later

VALGENT2 contribution towards hpv-primary screening in scotland

K Cuschieri & R Bhatia

Primary HPV screening in the US with the Cobas® assay

A C Cohen & W K Huh

Integrating HPV-screening and HPV vaccination in Central and Eastern Europe

M Poljak

Australia on-track to be the first country to achieve cervical cancer elimination

K Canfell, M Hall, K Simms, M Smith & M Saville

The BD Onclarity HPV assay: Key data pointing to clinical validity

M H Stoler & T C Wright Jr

Experiences with the use of HPV testing in cervical cancer screening in Sweden

J Dillner & M Elfström

Core elements of the new HPV-based cervical cancer screening programme in Italy

G Ronco

HPV-based cervical cancer screening in US

N Wentzensen & M Schiffman

HPV testing on self-samples: the evidence of Today

M Arbyn, S Smith & P Castle

Self-sampling to reach non-participating women

J Bonde & D Ejegod

HPV assays validated for primary cervical cancer screening

M Arbyn & P Hillemanns

HPV screening: DNA- versus RNAbased HPV Tests

T Iftner

Xpert HPV: Basis and key results in best trials

L Denny, R Saidu & L Kuhn

Italian consensus on cervical cancer screening in hpv vaccinated woman

P Giorgi Rossi, M T Sandri, L Mariani & F Carozzi

HPV DNA or HPV E6/E7 mRNA assays?

T Iftner

Interview Marc Arbyn

M Arbyn

VALGENT 4